Compare Stocks: FGEN, RNA, BNR, and SPRB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$18.00 +19.4%	$10.63	$6.79 ▼ $41.72	$173.02M	1.38	52,729 shs	135,974 shs
FGEN FibroGen	$9.77 +8.3%	$9.21	$4.85 ▼ $12.60	$39.57M	0.77	40,794 shs	31,125 shs
RNA Avidity Biosciences	$8.19 -1.7%	$11.90	$8.16 ▼ $16.77	$142.49M	N/A	371,333 shs	355,090 shs
SPRB Spruce Biosciences	$49.02 -0.8%	$51.30	$7.26 ▼ $240.00	$143.67M	3.31	104,375 shs	85,772 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	+19.44%	+33.14%	+82.20%	+118.74%	+97.59%
FGEN FibroGen	0.00%	0.00%	0.00%	0.00%	-21.08%
RNA Avidity Biosciences	-1.68%	-14.33%	-41.50%	-37.91%	-81.05%
SPRB Spruce Biosciences	-0.81%	-8.99%	-22.68%	-11.05%	+494.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$18.00 +19.4%	$10.63	$6.79 ▼ $41.72	$173.02M	1.38	52,729 shs	135,974 shs
FGEN FibroGen	$9.77 +8.3%	$9.21	$4.85 ▼ $12.60	$39.57M	0.77	40,794 shs	31,125 shs
RNA Avidity Biosciences	$8.19 -1.7%	$11.90	$8.16 ▼ $16.77	$142.49M	N/A	371,333 shs	355,090 shs
SPRB Spruce Biosciences	$49.02 -0.8%	$51.30	$7.26 ▼ $240.00	$143.67M	3.31	104,375 shs	85,772 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	+19.44%	+33.14%	+82.20%	+118.74%	+97.59%
FGEN FibroGen	0.00%	0.00%	0.00%	0.00%	-21.08%
RNA Avidity Biosciences	-1.68%	-14.33%	-41.50%	-37.91%	-81.05%
SPRB Spruce Biosciences	-0.81%	-8.99%	-22.68%	-11.05%	+494.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNR Burning Rock Biotech	1.00	Sell	N/A	N/A
FGEN FibroGen	1.00	Sell	N/A	N/A
RNA Avidity Biosciences	2.25	Hold	$63.75	678.39% Upside
SPRB Spruce Biosciences	2.77	Moderate Buy	$158.33	223.00% Upside

Current Analyst Ratings Breakdown

Latest FGEN, RNA, BNR, and SPRB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	SPRB Spruce Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$144.00
9/18/2026	SPRB Spruce Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/17/2026	SPRB Spruce Biosciences	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$149.00
9/16/2026	SPRB Spruce Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/10/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	SPRB Spruce Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	SPRB Spruce Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	SPRB Spruce Biosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$123.00 ➝ $104.00
8/14/2026	RNA Avidity Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
8/13/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNR Burning Rock Biotech	$77.16M	2.45	N/A	N/A	$7.28 per share	2.47
FGEN FibroGen	$29.62M	1.34	N/A	N/A	($50.89) per share	-0.19
RNA Avidity Biosciences	$35.84M	3.91	N/A	N/A	N/A	∞
SPRB Spruce Biosciences	$4.91M	28.65	N/A	N/A	$39.72 per share	1.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNR Burning Rock Biotech	-$7.92M	-$0.87	N/A	N/A	N/A	-13.60%	-12.98%	-8.59%	11/17/2026 (Estimated)
FGEN FibroGen	-$47.58M	$53.48	0.18	N/A	N/A	2,598.55%	N/A	-26.27%	N/A
RNA Avidity Biosciences	N/A	-$2.15	N/A	N/A	N/A	N/A	N/A	N/A	11/12/2026 (Estimated)
SPRB Spruce Biosciences	-$38.97M	-$39.78	N/A	N/A	N/A	N/A	-123.53%	-90.35%	11/9/2026 (Estimated)

Latest FGEN, RNA, BNR, and SPRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/10/2026	Q2 2026	BNR Burning Rock Biotech	-$2.2883	-$0.20	+$2.0883	-$0.25	$19.21 million	$19.84 million
8/13/2026	Q2 2026	RNA Avidity Biosciences	-$1.42	-$1.18	+$0.24	-$1.18	$0.67 million	$3.00 million
8/12/2026	Q2 2026	SPRB Spruce Biosciences	-$5.79	-$6.68	-$0.89	-$6.68	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNR Burning Rock Biotech	N/A	N/A	N/A	N/A	N/A
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNR Burning Rock Biotech	N/A	3.05	2.90
FGEN FibroGen	N/A	3.71	3.60
RNA Avidity Biosciences	N/A	8.73	8.73
SPRB Spruce Biosciences	0.05	9.23	9.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNR Burning Rock Biotech	30.03%
FGEN FibroGen	72.71%
RNA Avidity Biosciences	N/A
SPRB Spruce Biosciences	91.71%

Insider Ownership

Company	Insider Ownership
BNR Burning Rock Biotech	30.30%
FGEN FibroGen	3.07%
RNA Avidity Biosciences	3.83%
SPRB Spruce Biosciences	4.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNR Burning Rock Biotech	667	10.52 million	7.33 million	Not Optionable
FGEN FibroGen	570	4.05 million	3.92 million	Optionable
RNA Avidity Biosciences	190	17.11 million	16.45 million	Optionable
SPRB Spruce Biosciences	8	2.87 million	2.75 million	Optionable

FGEN, RNA, BNR, and SPRB Headlines

Recent News About These Companies

Citizens Jmp Reaffirms "Market Outperform" Rating for Spruce Biosciences (NASDAQ:SPRB)

September 24 at 9:23 AM | marketbeat.com

Spruce Biosciences (SPRB) Reiterated at Market Outperform by Citizens on TA-ERT Therapy Lead

September 24 at 8:00 AM | streetinsider.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Consensus Rating of "Moderate Buy" by Analysts

September 23 at 3:36 AM | americanbankingnews.com

Spruce Biosciences (NASDAQ:SPRB) Coverage Initiated at Lake Street Capital

September 19, 2026 | americanbankingnews.com

Lake Street initiates coverage of Spruce Biosciences at buy

September 18, 2026 | msn.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Recommendation of "Moderate Buy" from Brokerages

September 18, 2026 | marketbeat.com

Lake Street Capital Initiates Coverage on Spruce Biosciences (NASDAQ:SPRB)

September 17, 2026 | marketbeat.com

Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | businesswire.com

Oppenheimer Sticks to Its Buy Rating for Spruce Biosciences (SPRB)

August 28, 2026 | theglobeandmail.com

Q3 EPS Estimates for Spruce Biosciences Cut by HC Wainwright

August 28, 2026 | marketbeat.com

Spruce Biosciences stock gains after analyst backs regulatory progress

August 27, 2026 | finance.yahoo.com

Spruce Biosciences Announces Launch of MPS3BStudy.com

August 26, 2026 | finance.yahoo.com

AWM Investment Company Inc. Makes New $7.94 Million Investment in Spruce Biosciences, Inc. $SPRB

August 26, 2026 | marketbeat.com

Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026

August 24, 2026 | finance.yahoo.com

Spruce Biosciences Inc.

August 16, 2026 | marketwatch.com

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

August 12, 2026 | aol.comA

Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences

August 12, 2026 | finance.yahoo.com

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

August 3, 2026 | finance.yahoo.com

Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer

July 27, 2026 | finance.yahoo.com

Spruce Biosciences Names Adrian Quartel Chief Medical Officer

July 27, 2026 | tipranks.com

Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

July 8, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

FGEN, RNA, BNR, and SPRB Company Descriptions

Burning Rock Biotech NASDAQ:BNR

$18.00 +2.93 (+19.44%)

Closing price 09/24/2026 03:59 PM Eastern

Extended Trading

$17.75 -0.25 (-1.39%)

As of 09/24/2026 07:30 PM Eastern

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

FibroGen NASDAQ:FGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Avidity Biosciences NASDAQ:RNA

$8.19 -0.14 (-1.68%)

As of 09/24/2026 04:00 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Spruce Biosciences NASDAQ:SPRB

$49.02 -0.40 (-0.81%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$49.07 +0.05 (+0.10%)

As of 09/24/2026 07:53 PM Eastern

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FGEN, RNA, BNR, and SPRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FGEN, RNA, BNR, and SPRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FGEN, RNA, BNR, and SPRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

FGEN, RNA, BNR, and SPRB Company Descriptions

Burning Rock Biotech NASDAQ:BNR

FibroGen NASDAQ:FGEN

Avidity Biosciences NASDAQ:RNA

Spruce Biosciences NASDAQ:SPRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FGEN, RNA, BNR, and SPRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FGEN, RNA, BNR, and SPRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FGEN, RNA, BNR, and SPRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

FGEN, RNA, BNR, and SPRB Company Descriptions

Burning Rock Biotech NASDAQ:BNR

FibroGen NASDAQ:FGEN

Avidity Biosciences NASDAQ:RNA

Spruce Biosciences NASDAQ:SPRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools